Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587608 | 0.84 | NPSR1 (0.50) | NPSR1L3MBTL1KMT2APOLBHPGD | |
| SCHEMBL13369577 | 0.81 | NPSR1 (0.52) | NPSR1L3MBTL1KMT2APOLBTP53 | |
| SCHEMBL31001781 | 0.78 | NPSR1 (0.45) | NPSR1L3MBTL1KMT2APOLBHPGD | |
| SCHEMBL28563324 | 0.77 | SMN1; SMN2 (0.47) | NPSR1L3MBTL1KMT2APOLBHPGD | |
| SCHEMBL25973886 | 0.77 | L3MBTL1 (0.49) | NPSR1L3MBTL1KMT2APOLBTP53 | |
| SCHEMBL14120046 | 0.76 | PKM (0.51) | PKMTSHRKMT2AMEN1HPGD | |
| SCHEMBL23943148 | 0.75 | NPSR1 (0.47) | NPSR1L3MBTL1KMT2APOLBTP53 | |
| SCHEMBL25312921 | 0.75 | NPSR1 (0.47) | NPSR1L3MBTL1KMT2APOLBMEN1 | |
| SCHEMBL3825896 | 0.75 | NPSR1 (0.42) | NPSR1L3MBTL1KMT2APOLBMEN1 | |
| SCHEMBL20746019 | 0.74 | L3MBTL1 (0.58) | NPSR1L3MBTL1KMT2APOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161307-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-22 | — | — | US | disclosed |
| US-12215112-B2 | CD151 inhibitors | Esfam Biotech Pty Ltd (AU) | 2025-02-04 | — | — | US | disclosed |
| WO-2024254599-A1 | HPGD INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-4469454-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | Janssen Pharmaceutica NV (BE) | 2024-12-04 | — | — | EP | disclosed |
| US-20230365567-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| US-20230365567-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| US-20230365567-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| CN-116829558-A | Compounds of formula (I) | 艾斯法姆生物技术股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023141866-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023141866-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | WO | disclosed |
| WO-2022020889-A1 | METHOD OF TREATMENT OF CYTOMEGALOVIRUS | Esfam Biotech Pty Ltd (AU) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022020891-A1 | METHODS OF PROPHYLAXIS AND TREATMENT OF CORONA VIRUS | Esfam Biotech Pty Ltd (AU) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022020887-A1 | TREATMENT OF CD151 RELATED DISORDERS | Esfam Biotech Pty Ltd (AU) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022020888-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022020891-A1 | METHODS OF PROPHYLAXIS AND TREATMENT OF CORONA VIRUS | Esfam Biotech Pty Ltd (AU) | 2022-02-03 | — | — | WO | disclosed |
| EP-2539342-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8969376-B2 | Pyrazolopyrimidine compounds and their use as PDE10 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-03 | — | — | US | disclosed |
| EP-2539342-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| WO-2011105628-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365567-A1 | COMPOUNDS | CD81, CD47, CD59 | PKM 4516/4885NPSR1 211/4885L3MBTL1 4091/4885 |
| US-12215112-B2 | CD151 inhibitors | CD81, CD47, CD4 | PKM 4831/4885NPSR1 1917/4885L3MBTL1 3502/4885 |
| US-20250161307-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | SMOX, SRM, SMS | PKM 550/4885NPSR1 1352/4885L3MBTL1 1735/4885 |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE3B, PDE3A, PDE5A | PKM 296/4885NPSR1 2131/4885L3MBTL1 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.